Related Experiment Video

Updated: Feb 10, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.1K

[The advances of the drug therapy for pulmonary fibrosis]

Bing Cui1, Zhuo-Wei Hu

  • 1Institute of Meteria Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.

Sheng Li Ke Xue Jin Zhan [Progress in Physiology]
|September 30, 2008
PubMed

Insights

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no effective treatments. This review explores emerging therapies targeting key mechanisms like alveolar cells and oxidative stress for improved survival.

Area of Science:

  • Pulmonary Medicine
  • Fibrotic Diseases
  • Pharmacology

Context:

  • Idiopathic pulmonary fibrosis (IPF) is a severe, progressive, and fatal interstitial lung disease.
  • Current treatments offer limited survival benefits, with a median survival of approximately three years.
  • Understanding the molecular and cellular mechanisms of fibrosis is crucial for developing new therapies.

Purpose:

  • To review current clinical treatments for pulmonary fibrotic diseases.
  • To summarize novel therapeutic agents undergoing clinical trials for IPF.
  • To examine the prospects of new drugs targeting specific pathways involved in fibrosis.

Summary:

  • The review covers emerging drug targets including alveolar epithelial cells, myofibroblasts, angiogenesis inhibition, cytokine balance (TH1/TH2), and oxidative stress.
  • It synthesizes information on drugs in clinical trials aimed at these targets.
  • The focus is on the potential of these novel therapies to alter the course of IPF.

Impact:

  • Provides an overview of the current landscape and future directions for IPF treatment.
  • Highlights potential therapeutic strategies to improve patient survival and quality of life.
  • Informs researchers and clinicians about promising new drug development for fibrotic lung diseases.

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

958
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.8K

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
718
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
302
Drug Excretion: Pulmonary and Glandular Routes01:22

Drug Excretion: Pulmonary and Glandular Routes

Gaseous substances like general anesthetics are absorbed and excreted through the lungs via simple diffusion. This process depends on factors such as pulmonary blood flow, respiration rate, and the substance's solubility. Gaseous anesthetics like nitrous oxide with low blood solubility are excreted rapidly, while compounds like alcohol, with high blood and tissue solubility, are excreted slowly.
Drugs can also be excreted in breast milk, which is crucial for breastfeeding infants. The...
738
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.4K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
633
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
891